Haitong International: HANSOH PHARMA CDH17ADC authorized to Roche, total consideration exceeds 1.5 billion USD
I'm PortAI, I can summarize articles.
Haitong International released a research report stating that HANSOH PHARMA has signed a licensing agreement with Roche, under which HANSOH will receive an upfront payment of $80 million and up to $1.45 billion in milestone payments. The firm is optimistic about the normalization of milestone revenue for HANSOH PHARMA, expecting that revenue from innovative drugs will exceed 10 billion by 2025, with sales of Amivantamab expected to surpass 6 billion. Risks include lower-than-expected drug sales and risks associated with new drug development
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments